Gene therapy trial aims to halt vision loss in dry AMD

NCT ID NCT07158775

Recruiting now Disease control Sponsor: Bionic Sight LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new gene therapy called BS01 for people with geographic atrophy, a severe form of dry age-related macular degeneration that causes blind spots. The treatment uses a harmless virus to deliver a light-sensitive protein to the eye, aiming to restore or preserve vision. The trial involves 40 adults aged 50-85 and will first check safety, then measure if it improves eyesight compared to a sham procedure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY (GA) SECONDARY TO DRY AGE-RELATED MACULAR DEGENERATION (AMD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dry age related macular degeneration Geographic Atrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GEOGRAPHIC ATROPHY (GA) SECONDARY TO DRY AGE-RELATED MACULAR DEGENERATION (AMD)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

NJ Retina
RECRUITING

Edison, New Jersey, 08820, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••